Your browser doesn't support javascript.
loading
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez, Aranzazu; Pascual, Tomás; Perrone, Giuseppe; Morales, Serafin; de la Haba, Juan; González-Rivera, Milagros; Galván, Patricia; Zalfa, Francesca; Amato, Michela; Gonzalez, Lucia; Prats, Miquel; Rojo, Federico; Manso, Luis; Paré, Laia; Alonso, Immaculada; Albanell, Joan; Vivancos, Ana; González, Antonio; Matito, Judit; González, Sonia; Fernandez, Pedro; Adamo, Barbara; Muñoz, Montserrat; Viladot, Margarita; Font, Carme; Aya, Francisco; Vidal, Maria; Caballero, Rosalía; Carrasco, Eva; Altomare, Vittorio; Tonini, Giuseppe; Prat, Aleix; Martin, Miguel.
Affiliation
  • Fernandez-Martinez A; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Pascual T; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Perrone G; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Morales S; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • de la Haba J; Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.
  • González-Rivera M; Medical Oncology Deparment, Arnau de Vilanova de Lleida Universitary Hospital, Lleida, Spain.
  • Galván P; Medical Oncology Department, Reina Sofía University Hospital, Cordoba, Spain.
  • Zalfa F; Medical Oncology Department, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Universidad Complutense, Madrid, Spain.
  • Amato M; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Gonzalez L; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Prats M; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Rojo F; Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Manso L; Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Paré L; Medical Oncology Department, Quirón Hospital, Madrid, Spain.
  • Alonso I; Master of Breast Pathology, University of Barcelona, Barcelona, Spain.
  • Albanell J; Pathology Department, Fundación Jiménez Díaz Health Research Institute (IIS-FJD), Madrid, Spain.
  • Vivancos A; Medical Oncology Department, Doce de Octubre Hospital, Madrid, Spain.
  • González A; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Matito J; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • González S; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Fernandez P; Medical Oncology Department, Hospital del Mar, Barcelona, Spain.
  • Adamo B; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Muñoz M; Medical Oncology Department, MD Anderson Cancer Center, Madrid, Spain.
  • Viladot M; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Font C; Medical Oncology Department, Mutua de Terrassa Hospital, Barcelona, Spain.
  • Aya F; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Vidal M; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Caballero R; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Carrasco E; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Altomare V; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Tonini G; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Prat A; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Martin M; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Oncotarget ; 8(13): 21930-21937, 2017 Mar 28.
Article in En | MEDLINE | ID: mdl-28423537

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tamoxifen / Breast Neoplasms / Receptors, Estrogen / Biomarkers, Tumor / Risk Assessment / Receptor, ErbB-2 / Neoplasm Recurrence, Local Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Oncotarget Year: 2017 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tamoxifen / Breast Neoplasms / Receptors, Estrogen / Biomarkers, Tumor / Risk Assessment / Receptor, ErbB-2 / Neoplasm Recurrence, Local Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Oncotarget Year: 2017 Type: Article Affiliation country: Spain